Table 1.
Demographic and Clinical Characteristics of Immunocompromised Children With and Without Potential Pathogens Detected by BAL, 2001–2012
| Characteristic | Patients (n = 47) with potential pathogen isolated from BAL N (%) | Patients (n = 76) without potential pathogen from BAL N (%) | P |
|---|---|---|---|
| BAL | 84 (48) | 90 (52) | |
| Mean age at 1st BAL (range) | 9.4 years (0.7–18.5) | 10.2 years (0.4–18.9) | 0.45 |
| Sex | |||
| M | 28 (59.6) | 50 (65.8) | 0.56 |
| Race/ethnicity | |||
| White non‐Hispanic | 13 (27.6) | 25 (64.8) | 0.68 |
| Black | 4 (8.5) | 7 (9.2) | 1.00 |
| Hispanic | 13 (27.6) | 19 (25.0) | 0.83 |
| Asian | 2 (4.3) | 4 (5.3) | 1.00 |
| Other | 1 (2.1) | 1 (13.2) | 1.00 |
| Unknown | 14 (29.8) | 20 (26.3) | 0.68 |
| Underlying diagnosis | |||
| Acute myelogenous leukemia | 8 (17.0) | 14 (18.4) | 1.00 |
| Acute lymphocytic leukemia | 13 (27.6) | 17 (22.3) | 0.52 |
| Aplastic Anemia | 2 (4.3) | 11 (14.4) | 0.12 |
| Chronic myelogenous leukemia | 2 (4.3) | 0 | 0.14 |
| Hemophagocytic | |||
| lymphohistiocytosis | 4 (8.5) | 5 (6.6) | 0.73 |
| Hodgkin disease | 2 (4.3) | 2 (2.6) | 0.63 |
| Other malignant disorders | 5 (10.6) | 16 (21.0) | 0.70 |
| Other nonmalignant disorders 1 | 11 (23.4) | 11 (14.5) | 0.23 |
| HSCT Prior to BAL | 31 (70.0) | 44 (57.9) | 0.44 |
| Time from 1st HSCT to 1st BAL | |||
| ≤30 d | 8 (25.8) | 15 (34.1) | |
| >30 d | 23 (74.2) | 29 (65.9) | 0.61 |
| Degree of myeloablation | |||
| Myeloablative | 16 (51.6) | 25 (56.8) | 0.81 |
| Reduced toxicity | 7 (22.6) | 13 (29.5) | 0.60 |
| Reduced intensity | 8 (25.8) | 6 (13.6) | 0.23 |
| Received anti‐thymocyte globulin | 17 (54.8) | 21 (47.7) | 0.64 |
| Received alemtuzumab | 5 (16.1) | 10 (22.7) | 0.57 |
| Time period | |||
| 2001–2006 | 28 (59.6) | 30 (39.5) | |
| 2007–2012 | 19 (40.4) | 46 (60.5) | 0.041 |
HSCT, hematopoietic stem cell transplant.
1
Underwent HSCT prior to BAL. Other malignant and non‐malignant indications for HSCT included neuroblastoma, Langerhans cell histiocytosis, adrenoleukodystrophy, myelodysplastic syndrome, thalassemia, pansclerotic morphea and Wiskott–Aldrich syndrome.